Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT

Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT

Background: Children with juvenile idiopathic arthritis (JIA) are at risk of uveitis. The role of adalimumab (Humira®; AbbVie Inc., Ludwigshafen, Germany) in the management of uveitis in children needs to be determined. Objective: To compare the efficacy, safety and cost-effectiveness of adalimumab...

Full description

Bibliographic Details
Main Authors: Athimalaipet V Ramanan, Andrew D Dick, Ashley P Jones, Dyfrig A Hughes, Andrew McKay, Anna Rosala-Hallas, Paula R Williamson, Ben Hardwick, Helen Hickey, Naomi Rainford, Graeme Hickey, Ruwanthi Kolamunnage-Dona, Giovanna Culeddu, Catrin Plumpton, Eifiona Wood, Sandrine Compeyrot-Lacassagne, Patricia Woo, Clive Edelsten, Michael W Beresford
Format: Article
Language:English
Published: NIHR Journals Library 2019-04-01
Series:Health Technology Assessment
Subjects:
ADALIMUMAB
JUVENILE IDIOPATHIC ARTHRITIS
RANDOMISED CONTROLLED TRIAL
METHOTREXATE
OPHTHALMOLOGY
PAEDIATRIC
RHEUMATOLOGY
SAFETY
UVEITIS
Online Access:https://doi.org/10.3310/hta23150

Internet

https://doi.org/10.3310/hta23150

Similar Items